These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12749010)

  • 21. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience.
    Katz U; Kishner I; Magalashvili D; Shoenfeld Y; Achiron A
    Autoimmunity; 2006 Sep; 39(6):513-7. PubMed ID: 17060031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan.
    Muso E; Ito-Ihara T; Ono T; Imai E; Yamagata K; Akamatsu A; Suzuki K
    Jpn J Infect Dis; 2004 Oct; 57(5):S17-8. PubMed ID: 15507757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris.
    Bystryn JC; Jiao D
    Autoimmunity; 2006 Nov; 39(7):601-7. PubMed ID: 17101504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
    Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
    Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on treatment of immunologic abortion with low-dose intravenous immunoglobulin.
    Stricker RB; Winger EE
    Am J Reprod Immunol; 2005 Dec; 54(6):390-6. PubMed ID: 16305665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of intravenous immunoglobulin (IVIG) therapy.
    Katz U; Achiron A; Sherer Y; Shoenfeld Y
    Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial.
    Rossi J; Bayram M; Udelson JE; Lloyd-Jones D; Adams KF; Oconnor CM; Stough WG; Ouyang J; Shin DD; Orlandi C; Gheorghiade M
    Acute Card Care; 2007; 9(2):82-6. PubMed ID: 17573581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in biochemical, hematological and immunological profiles after low-dose intravenous immunoglobulin administration in patients with hypogammaglobulinemia.
    Berlana D; Vidaller A; Jódar R; Fort E; Domingo A; Pastó L
    Transfus Clin Biol; 2005 Dec; 12(6):433-40. PubMed ID: 16616571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery.
    Buda S; Riefolo A; Biscione R; Goretti E; Cattabriga I; Grillone G; Bacchi-Reggiani L; Pacini D
    J Cardiothorac Vasc Anesth; 2005 Aug; 19(4):440-5. PubMed ID: 16085247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carbamazepine-induced hyponatremia: assessment of risk factors.
    Kuz GM; Manssourian A
    Ann Pharmacother; 2005 Nov; 39(11):1943-6. PubMed ID: 16189283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia.
    Gheorghiade M; Gottlieb SS; Udelson JE; Konstam MA; Czerwiec F; Ouyang J; Orlandi C;
    Am J Cardiol; 2006 Apr; 97(7):1064-7. PubMed ID: 16563917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case of pulmonary hyalinizing granuloma characterized by pseudohyponatremia due to hyperproteinemia.
    Yamauchi M; Kamejima S; Yamamoto I; Ohkido I; Araya J; Yokoo T
    Respir Med Case Rep; 2023; 43():101854. PubMed ID: 37124054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up.
    Sami N; Letko E; Androudi S; Daoud Y; Foster CS; Ahmed AR
    Ophthalmology; 2004 Jul; 111(7):1380-2. PubMed ID: 15234140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Multifocal motor neuropathy: a retrospective study of the response to high-dose intravenous immunoglobulin (IVIg) and current perspectives for diagnosis and treatment].
    Léger JM; Viala K; Maisonobe T; Bouche P
    Bull Acad Natl Med; 2007 Oct; 191(7):1395-407; discussion 1407-9. PubMed ID: 18447061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions.
    Rigas M; Tandan R; Sterling RJ
    J Clin Neuromuscul Dis; 2008 Dec; 10(2):52-5. PubMed ID: 19169090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Side effects of intravenous immunoglobulins in neurological autoimmune disorders--a prospective study.
    Stangel M; Kiefer R; Pette M; Smolka MN; Marx P; Gold R
    J Neurol; 2003 Jul; 250(7):818-21. PubMed ID: 12883923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study.
    Verbalis JG; Zeltser D; Smith N; Barve A; Andoh M
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):159-68. PubMed ID: 18034777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia.
    Rembratt A; Riis A; Norgaard JP
    Neurourol Urodyn; 2006; 25(2):105-9. PubMed ID: 16304673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial.
    Gheorghiade M; Rossi JS; Cotts W; Shin DD; Hellkamp AS; Piña IL; Fonarow GC; DeMarco T; Pauly DF; Rogers J; DiSalvo TG; Butler J; Hare JM; Francis GS; Stough WG; O'Connor CM
    Arch Intern Med; 2007 Oct; 167(18):1998-2005. PubMed ID: 17923601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections.
    Carbone J; Sarmiento E; Palomo J; Fernandez-Yañez J; Muñoz P; Bouza E; Rodríguez-Molina J; Lanio N; Fernandez-Cruz E
    Transplant Proc; 2007 Sep; 39(7):2385-8. PubMed ID: 17889198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.